Clinical Trials / Browse by Phase / Phase 2

Browse by Phase

Phase 2 Clinical Trials

Phase 2 trials study whether a drug works in people with a specific disease or condition. These studies enroll 100–300 participants and also continue to evaluate safety.

Total Trials

1,083

Recruiting Now

1,083

Top Conditions in Phase 2

Breast Cancer (27) Prostate Cancer (17) Multiple Myeloma (15) Head and Neck Squamous Cell Carcinoma (12) Acute Myeloid Leukemia (11) Non-Small Cell Lung Cancer (10) NSCLC (9) Ovarian Cancer (9) Gastric Cancer (9) Esophageal Squamous Cell Carcinoma (9)

Frequently Asked Questions — Phase 2 Trials

What does a Phase 2 clinical trial evaluate?

Phase 2 trials assess whether a drug or treatment works in people with a specific disease or condition. Enrolling 100–300 participants, these studies collect preliminary efficacy data while continuing to monitor safety and identify the optimal dosing regimen. A successful Phase 2 outcome is required to advance to large-scale Phase 3 testing.

How long do Phase 2 trials typically take?

Phase 2 clinical trials typically run for 1–4 years, depending on the condition, endpoint complexity, and enrollment rate. Rare disease trials or those with long-term outcome measures may run longer. Many sponsors run Phase 2 studies at multiple sites simultaneously to accelerate recruitment.

Who can participate in a Phase 2 clinical trial?

Eligibility for Phase 2 trials is defined by specific inclusion and exclusion criteria. Participants are typically patients diagnosed with the condition under study and may or may not have received prior treatment. Age, disease stage, comorbidities, and laboratory values are common eligibility factors. Review each trial's criteria on ClinicalTrials.gov for specific requirements.

Active Phase 2 Studies

NCT06887777 Phase 2

Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patien...

Pyruvate Dehydrogenase Complex Deficiency Disease

Assistance Publique - Hôpitaux

NCT06591819 Phase 2

Hypofractionated WPPT With HDR Boost

Prostate Cancer

Abramson Cancer Center at Penn

NCT07434271 Phase 2

Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory La...

Premature Ejaculation

NCT06988956 Phase 2

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esoph...

Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital

NCT04519151 Phase 2

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian Neoplasms

Sheba Medical Center

NCT05355051 Phase 2

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patient...

Hodgkin's Lymphoma

M.D. Anderson Cancer Center

NCT06954831 Phase 2

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for...

Anatomic Stage I Breast Cancer AJCC v8

City of Hope Medical Center

NCT02393157 Phase 2

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Non-Hodgkin Lymphoma

New York Medical College

NCT07489430 Phase 2

DaxibotulinumtoxinA for Blepharospasm

Blepharospasm of Both Eyelids

University of Pennsylvania

NCT06466122 Phase 2

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL o...

Chronic Lymphocytic Leukemia

NCT07186101 Phase 2

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately ...

Ulcerative Colitis

United States, Austria, Brazil

Eli Lilly and Company

NCT06997081 Phase 2

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

Multiple Myeloma

University of Miami

NCT05855811 Phase 2

PREventing Second Cancers With DOSTARlimab

Recurrent Cancer

Centre Leon Berard

NCT07750951 Phase 2

Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintil...

MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

Xijing Hospital

NCT05757219 Phase 2

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Diffuse Large B Cell Lymphoma

H. Lee Moffitt Cancer Center a

NCT07605728 Phase 2

Probiotics for Abemaciclib-Induced Abdominal Discomfort.

Leeuwenhoek Laboratories Co. L

NCT07392229 Phase 2

Zanubritnib and Anti-MAG Neuropathy

Anti-MAG IgM-associated Demyelinating Polyneuropathy

Azienda Ospedaliera di Padova

NCT03412877 Phase 2

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Re...

Endocrine Tumors

National Cancer Institute (NCI

NCT06714357 Phase 2

ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resi...

Colorectal Cancer Metastatic

National Cancer Institute, Nap

NCT06797401 Phase 2

Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mix...

Ribocure Pharmaceuticals AB

NCT07517107 Phase 2

Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Ca...

Fudan University

NCT07251595 Phase 2

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental V...

Non-segmental Vitiligo

Jiangsu HengRui Medicine Co.,

NCT04789681 Phase 2

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

M.D. Anderson Cancer Center

NCT06403267 Phase 2

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With o...

Acute Ischemic Stroke

NCT06642545 Phase 2

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ±...

RemeGen Co., Ltd.

Page 6 of 44 — 1,083 trials total

← Prev Next →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology